Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications | Zendy

David Austin | Zendy; Keith G. Oldroyd | Zendy; Alex McConnachie | Zendy; Rachel D. Slack | Zendy; Hany Eteiba | Zendy; Andrew D. Flapan | Zendy; Kevin Jennings | Zendy; Robin J. Northcote | Zendy; A C H Pell | Zendy; Ian R. Starkey | Zendy; Jill P. Pell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications

Author(s) -

David Austin,

Keith G. Oldroyd,

Alex McConnachie,

Rachel D. Slack,

Hany Eteiba,

Andrew D. Flapan,

Kevin Jennings,

Robin J. Northcote,

A C H Pell,

Ian R. Starkey,

Jill P. Pell

Publication year - 2008

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.108.769042

Subject(s) - bare metal , medicine , off label use , drug , stent , radiology , restenosis , pharmacology

The US Food and Drug Administration recently concluded that data on off-label drug-eluting stent (DES) safety are limited. However, in actual clinical practice, DES are often used for off-label indications, and observational studies demonstrate that complications are higher when compared with on-label use. We aimed to determine whether clinical outcomes differ after DES and bare-metal stent implantation in a patient cohort defined by DES off-label indications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research